SS-31 vs 5-Amino-1MQ
SS-31, known as elamipretide, is a mitochondria-targeted tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, stabilising cristae architecture and improving electron transport efficiency. It has been through randomised controlled trials in Barth syndrome, primary mitochondrial myopathy, heart failure and Leber hereditary optic neuropathy, and in September 2025 received FDA accelerated approval for Barth syndrome. 5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase, an enzyme that methylates nicotinamide and thereby consumes S-adenosylmethionine while diverting nicotinamide away from NAD+ salvage; its entire efficacy record is rodent and in vitro. Both are sold on a broadly mitochondrial rationale, which is why they are compared. No published paper names both. Searches of PubMed and of Europe PMC across full text found records that mention elamipretide alongside NNMT, but none that names 5-Amino-1MQ, so every comparison below is drawn from two separate literatures.
No study has compared them directly.
Everything below is drawn from separate studies that used different models, endpoints and species. That is a real limit on what can be concluded, not a formality.
No study has administered or tested SS-31 and 5-Amino-1MQ together, and no publication names both. Searches were run against PubMed by title and abstract and against Europe PMC across full text, using elamipretide and Szeto-Schiller for the first compound and 5-amino-1-methylquinolinium and nicotinamide N-methyltransferase for the second. Full-text searching returned a small number of heart failure and ageing papers that mention elamipretide and the NNMT enzyme within the same document, but on checking, none of them names 5-Amino-1MQ or any NNMT inhibitor as a tested compound, so none qualifies as evidence engaging both. The nearest adjacent publication is a 2020 Aging Cell study titled SS-31 and NMN: Two paths to improve metabolism and function in aged hearts, which paired the peptide with the NAD+ precursor nicotinamide mononucleotide rather than with an NNMT inhibitor. The comparison below is therefore indirect throughout.
Side by side.
| SS-31 | 5-Amino-1MQ | |
|---|---|---|
| Evidence maturity | Approved drug | Preclinical only |
| Studies cited here | 16 | 15 |
| Published 2023 or later | 11 | 8 |
| Newest paper | 2026 | 2026 |
| Sequence and origin | A synthetic tetrapeptide designed to accumulate in the inner mitochondrial membrane. It has no endogenous counterpart but acts on an endogenous membrane lipid, cardiolipin. | A synthetic quinolinium small molecule rather than a peptide, designed to inhibit a cytosolic methyltransferase. |
| Mechanism as described in the literature | Binding to cardiolipin in the inner mitochondrial membrane, stabilising cristae architecture and improving electron transport efficiency and ATP synthesis. The foundational 2013 paper demonstrated cardiolipin binding, cristae protection and restored ATP production in a rat kidney ischaemia-reperfusion model. | Inhibition of nicotinamide N-methyltransferase, reported in rodents to raise tissue NAD+, suppress lipogenic gene expression and alter polyamine flux, with AMPK activation described in aged skeletal muscle. |
| Size of the evidence base | Sixteen studies in this library, the majority randomised controlled trials in humans, including a phase 3 trial and several phase 2 designs, alongside animal work. | Fifteen studies in this library, none of them human. The set is rodent in vivo work, enzyme kinetics and reviews of the target. |
| Best-characterised finding | Sustained functional improvement in Barth syndrome. A 168-week open-label extension of the TAZPOWER trial reported a cumulative six-minute walk distance improvement of 96.1 m relative to extension baseline, with improvements also reported in fatigue scores and cardiac function measures. | Reversal of diet-induced obesity in mice without reduced food intake, plus improved grip strength and muscle regeneration in aged mice, with rising tissue NAD+ reported as the marker of target engagement. |
| Human data | Extensive and mixed. Randomised controlled trials exist in Barth syndrome, primary mitochondrial myopathy, heart failure with reduced ejection fraction and Leber hereditary optic neuropathy, and a single-dose study in healthy older adults reported raised skeletal muscle mitochondrial energetic capacity. The phase 3 MMPOWER-3 trial in 218 participants missed its primary endpoints, as did the phase 2 heart failure and optic neuropathy trials. | None. No human clinical trial has been published, and human pharmacokinetics, oral bioavailability, safety and target engagement are uncharacterised. |
| Evidence maturity | Approved for one rare disease. Accelerated approval was granted in September 2025 to improve muscle strength in Barth syndrome patients meeting a weight threshold, on the basis of an improvement in knee extensor muscle strength, with continued approval contingent on confirmatory trials. | Preclinical only. A 2026 review in Trends in Pharmacological Sciences framed clinical translation of NNMT inhibitors as an emerging rather than an established prospect. |
| Recency of primary research | Active on both fronts, with 2026 publications including two rat models of heart failure with preserved ejection fraction, a mitochondrial trifunctional protein deficiency study and a pharmacology review following approval. | Active but preclinical, with 2025 and 2026 work covering inhibitor turnover kinetics, a peripheral artery disease model and translational reviews. |
| Evidence for use in healthy individuals | Almost none. The single relevant study is a randomised, double-blind, placebo-controlled single-dose trial in 39 healthy older adults that measured a short-term bioenergetic endpoint by magnetic resonance spectroscopy, not exercise performance. No controlled trial has examined exercise capacity, athletic performance, longevity or body composition in healthy people. | None in any population. Every efficacy finding derives from rodent models or in vitro enzymology, so no claim about healthy human use rests on human data. |
And what it does not.
Nothing published compares these two, and the reason they are paired at all is a shared vocabulary rather than a shared experiment. SS-31 is the better-evidenced compound by a wide margin: it has a defined molecular target, a foundational mechanistic paper, multiple randomised human trials and a regulatory approval, but that approval covers one rare genetic disorder, was granted on a muscle-strength surrogate in a very small cohort, and is contingent on confirmatory trials. Its largest randomised trial missed its primary endpoints, as did its heart failure and optic neuropathy trials. 5-Amino-1MQ has an internally consistent rodent literature and a validated enzyme target, and no human exposure at all. For the use that usually prompts the comparison, mitochondrial support or performance in healthy people, neither has controlled human evidence: SS-31 has one single-dose bioenergetic study in healthy older adults measuring a laboratory endpoint, and 5-Amino-1MQ has nothing.
Common questions.
- Does the approval of SS-31 mean it is proven for general mitochondrial support?
No. Accelerated approval was granted in September 2025 for Barth syndrome, an X-linked disorder of cardiolipin remodelling, to improve muscle strength in adult and paediatric patients above a weight threshold, and it rested on an improvement in knee extensor muscle strength in a very small cohort. Continued approval is contingent on confirmatory trials. There are no controlled trials of elamipretide in healthy individuals for exercise capacity, athletic performance, longevity or body composition.
- What happened in the largest SS-31 trial?
The phase 3 MMPOWER-3 trial randomised 218 participants with primary mitochondrial myopathy to elamipretide or placebo for 24 weeks and did not meet its primary endpoints of change in six-minute walk test distance or fatigue score, though the drug was generally well tolerated. A later post hoc genotype-stratified analysis reported improvement on the six-minute walk test in participants with mtDNA replisome disorders and in those with chronic progressive external ophthalmoplegia, while the overall population did not improve.
- Do the two compounds act on mitochondria in the same way?
Not as described in the literature. SS-31 acts physically at the inner mitochondrial membrane, binding cardiolipin to stabilise cristae architecture and improve electron transport efficiency and ATP synthesis. 5-Amino-1MQ acts in the cytosol on a methyltransferase, altering nicotinamide handling, NAD+ availability, methylation potential and polyamine flux, with downstream effects on mitochondrial metabolism inferred rather than measured at the membrane. No study has examined whether the two mechanisms interact.
- Is there any human evidence that SS-31 changes muscle energetics in people without disease?
One study addressed a related question. A randomised, double-blind, placebo-controlled single-dose trial in 39 healthy older adults used phosphorus magnetic resonance spectroscopy of skeletal muscle and reported that a single infusion raised in vivo mitochondrial energetic capacity relative to placebo immediately afterwards. That was a short-term bioenergetic measurement rather than an exercise performance or functional endpoint, and it involved a single dose rather than a course of treatment.
- Why do the NNMT findings not transfer to a claim about mitochondrial function in humans?
Because they have not been tested in humans at all. The muscle findings for NNMT inhibition, including grip strength gains in aged sedentary mice and improved regenerative capacity in aged skeletal muscle, come from rodent models, and the associated increases in NAD+ and AMPK activation were measured in mouse tissue. No biomarker-controlled human study has confirmed target engagement for this compound, so there is no basis for assuming that either the biochemical or the functional result reproduces in people.
For research purposes only. Not for human consumption, diagnosis, treatment, or prevention of any condition. Nothing on this page is medical advice, and no comparison here should be read as a recommendation of either compound.